Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
ELV Stock Forecast 2026-2027
$378.07
Current Price
$82.10B
Market Cap
Buy 14
Hold 8
Sell 0
Wall St Analyst Ratings
Distance to ELV Price Targets
+25.4%
To High Target of $474.00
+3.4%
To Median Target of $391.00
-12.5%
To Low Target of $331.00
ELV Price Momentum
+1.4%
1 Week Change
+21.4%
1 Month Change
-6.6%
1 Year Change
+7.9%
Year-to-Date Change
-10.9%
From 52W High of $424.24
+38.1%
From 52W Low of $273.71
📊 TOP ANALYST CALLS
Did ELV Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Elevance Health is one of their latest high-conviction picks.
Latest ELV Stock Price Targets & Analyst Predictions
Based on our analysis of 27 Wall Street analysts, ELV has a bullish consensus with a median price target of $391.00 (ranging from $331.00 to $474.00). The overall analyst rating is Strong Buy (8.3/10). Currently trading at $378.07, the median forecast implies a 3.4% upside. This outlook is supported by 14 Buy, 8 Hold, and 0 Sell ratings.
Conversely, the most conservative target is provided by Michael Ha at Baird, suggesting a 12.5% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ELV Analyst Ratings
14
Buy
8
Hold
0
Sell
ELV Price Target Range
Low
$331.00
Average
$391.00
High
$474.00
Current: $378.07
Latest ELV Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ELV.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 29, 2026 | B of A Securities | Kevin Fischbeck | Buy | Upgrade | $435.00 |
| Apr 28, 2026 | JP Morgan | Lisa Gill | Overweight | Maintains | $411.00 |
| Apr 24, 2026 | Guggenheim | Jason Cassorla | Buy | Maintains | $399.00 |
| Apr 24, 2026 | Barclays | Andrew Mok | Overweight | Maintains | $408.00 |
| Apr 23, 2026 | Evercore ISI Group | Elizabeth Anderson | In-Line | Maintains | $360.00 |
| Apr 23, 2026 | Baird | Michael Ha | Neutral | Maintains | $331.00 |
| Apr 20, 2026 | Jefferies | David Windley | Buy | Maintains | $391.00 |
| Apr 13, 2026 | Truist Securities | David Macdonald | Buy | Maintains | $375.00 |
| Apr 8, 2026 | Evercore ISI Group | Elizabeth Anderson | In-Line | Initiates | $345.00 |
| Mar 11, 2026 | Mizuho | Ann Hynes | Outperform | Maintains | $350.00 |
| Feb 2, 2026 | Truist Securities | David Macdonald | Buy | Maintains | $390.00 |
| Feb 2, 2026 | JP Morgan | Lisa Gill | Overweight | Maintains | $397.00 |
| Jan 30, 2026 | Barclays | Andrew Mok | Overweight | Maintains | $393.00 |
| Jan 30, 2026 | Wells Fargo | Stephen Baxter | Overweight | Maintains | $391.00 |
| Jan 29, 2026 | Guggenheim | Jason Cassorla | Buy | Maintains | $396.00 |
| Jan 22, 2026 | Guggenheim | Jason Cassorla | Buy | Maintains | $414.00 |
| Jan 8, 2026 | Wolfe Research | Justin Lake | Outperform | Upgrade | $425.00 |
| Jan 7, 2026 | Wells Fargo | Stephen Baxter | Overweight | Maintains | $424.00 |
| Jan 5, 2026 | Barclays | Andrew Mok | Overweight | Maintains | $404.00 |
| Dec 19, 2025 | Deutsche Bank | George Hill | Hold | Downgrade | $320.00 |
Elevance Health, Inc. (ELV) Competitors
The following stocks are similar to Elevance Health based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
ELV
Elevance Health
mkt cap
82.10B
Elevance Health, Inc. (ELV) Financial Data
Elevance Health, Inc. has a market capitalization of $82.10B with a P/E ratio of 16.0x. The company generates $200.42B in trailing twelve-month revenue with a 2.6% profit margin.
Revenue growth is +2.6% quarter-over-quarter, while maintaining an operating margin of +5.3% and return on equity of +12.1%.
Valuation Metrics
Market Cap
$82.10B
Enterprise Value
$77.01B
P/E Ratio
16.0x
PEG Ratio
-1.0x
Price/Sales
0.4x
Growth & Margins
Revenue Growth (YoY)
+2.6%
Gross Margin
N/A
Operating Margin
+5.3%
Net Margin
+2.6%
EPS Growth
-19.2%
Financial Health
Cash/Price Ratio
+45.2%
Current Ratio
1.5x
Debt/Equity
72.3x
ROE
+12.1%
ROA
+4.0%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Elevance Health, Inc. (ELV) Business Model
About Elevance Health, Inc.
What They Do
Provides integrated health solutions and services.
Business Model
The company operates through various segments, primarily generating revenue from health benefits plans, pharmacy services, and integrated care solutions. It serves a wide range of customers, including individuals, families, and employers, through a network of health plans and managed care options. By offering comprehensive services that address physical, behavioral, and social health needs, the company aims to improve health outcomes and affordability.
Additional Information
Founded in 1944 and headquartered in Indianapolis, Indiana, the company is a key player in the U.S. healthcare market, leveraging digital tools and data insights to enhance care delivery. Its partnerships with government agencies and providers further strengthen its position in the healthcare ecosystem.
Company Information
Sector
Healthcare
Industry
Healthcare Plans
Employees
96,129
CEO
Ms. Gail Koziara Boudreaux
Country
United States
IPO Year
2022
Website
www.elevancehealth.comElevance Health, Inc. (ELV) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
ENSG Tops Q1 EPS Estimates on Patient Growth, Raises '26 Outlook
Ensign Group tops Q1 EPS estimates as occupancy gains and acquisitions fuel growth, while higher costs and a slight revenue miss temper results.
May 05, 2026
By Zacks Equity Research
Analyst Blog
Pediatrix Medical Q1 Earnings Beat Estimates on Same-Unit Strength
Pediatrix Medical Group tops Q1 estimates as stronger reimbursements and same-unit gains lift results despite lower patient volumes.
May 05, 2026
By Zacks Equity Research
Analyst Blog
Acadia Healthcare Q1 Earnings Beat Estimates on Rising Patient Days
ACHC Q1 tops estimates with 37 cents EPS and 7.6% revenue growth, driven by higher patient days and admissions despite shorter stays and rising costs.
May 04, 2026
By Zacks Equity Research
Analyst Blog
Latest News
Quick Summary
Major insurers reported strong first-quarter results, boosting investor sentiment, despite ongoing challenges with rising medical costs and incomplete claims data. The second quarter will be critical.
Why It Matters
Strong Q1 results boost sentiment for major insurers, but potential lag in medical cost data raises concerns for Q2 performance. Investors may face volatility as claims processing affects earnings visibility.
Source: CNBC
Market Sentiment:
Negative
Quick Summary
Elevance Health aims to address mental health challenges amid rising awareness, as nearly 20% of Americans face mental health issues annually, highlighting a critical need for funding and improvements.
Why It Matters
Elevance Health's focus on mental health highlights growth potential in healthcare investments, addressing a critical need and signaling opportunities in mental health services and innovation.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Don Lair discusses options income and dividend strategies, emphasizing stable investment approaches that can support retirement funding.
Why It Matters
Focus on options income and dividend strategies indicates a move towards stable, long-term investments, appealing to risk-averse investors seeking reliable retirement funding.
Source: 24/7 Wall Street
Market Sentiment:
Negative
Quick Summary
Elevance Health is addressing rising healthcare costs for small businesses, which have increased 26% over five years, by providing solutions for competitive benefits and improved health outcomes.
Why It Matters
Elevance Health's initiatives to mitigate rising healthcare costs for small businesses could enhance their competitive edge, potentially boosting client retention and revenue growth, impacting stock performance positively.
Source: Business Wire
Market Sentiment:
Neutral
Elevance Health Names Best in Class Primary Care Practices in Care Provider Recognition Program
9 days ago
Quick Summary
Elevance Health recognized 45 top primary care providers in its annual Care Provider Recognition Program, highlighting excellence among its network of 7,200 value-based partners.
Why It Matters
Elevance Health's recognition of top primary care providers enhances its reputation, potentially boosting patient enrollment and investor confidence in its growth and quality of care.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Elevance Health raised its annual profit forecast, indicating effective management of medical costs.
Why It Matters
Elevance Health's increased profit forecast signals strong financial health and effective cost management, potentially boosting investor confidence and stock performance.
Source: Reuters
Market Sentiment:
Positive
Frequently Asked Questions About ELV Stock
What is Elevance Health, Inc.'s (ELV) stock forecast for 2026?
Based on our analysis of 27 Wall Street analysts, Elevance Health, Inc. (ELV) has a median price target of $391.00. The highest price target is $474.00 and the lowest is $331.00.
Is ELV stock a good investment in 2026?
According to current analyst ratings, ELV has 14 Buy ratings, 8 Hold ratings, and 0 Sell ratings. The stock is currently trading at $378.07. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ELV stock?
Wall Street analysts predict ELV stock could reach $391.00 in the next 12 months. This represents a 3.4% increase from the current price of $378.07. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Elevance Health, Inc.'s business model?
The company operates through various segments, primarily generating revenue from health benefits plans, pharmacy services, and integrated care solutions. It serves a wide range of customers, including individuals, families, and employers, through a network of health plans and managed care options. By offering comprehensive services that address physical, behavioral, and social health needs, the company aims to improve health outcomes and affordability.
What is the highest forecasted price for ELV Elevance Health, Inc.?
The highest price target for ELV is $474.00 from at , which represents a 25.4% increase from the current price of $378.07.
What is the lowest forecasted price for ELV Elevance Health, Inc.?
The lowest price target for ELV is $331.00 from Michael Ha at Baird, which represents a -12.5% decrease from the current price of $378.07.
What is the overall ELV consensus from analysts for Elevance Health, Inc.?
The overall analyst consensus for ELV is bullish. Out of 27 Wall Street analysts, 14 rate it as Buy, 8 as Hold, and 0 as Sell, with a median price target of $391.00.
How accurate are ELV stock price projections?
Stock price projections, including those for Elevance Health, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: May 10, 2026 7:10 PM UTC